SF2370 is an omnibus cannabis policy bill that makes broad changes to Minnesota’s cannabis, hemp, and medical cannabis laws. It updates the Office of Cannabis Management’s role, including adding it to the state’s tribal consultation framework and transferring medical cannabis program authority from the Department of Health to the Office of Cannabis Management. The bill revises rules for medical cannabis manufacturers, patient registry operations, testing, labeling, transportation, data practices, and distribution, while also expanding access for visiting patients and recognizing tribal medical cannabis programs and tribal medical cannabis patients.
The bill also significantly revises the state’s hemp and lower-potency hemp edible framework. It creates a new lower-potency hemp edible wholesaler license, adds delivery and export-related endorsements, sets product limits and packaging standards, and regulates imported hemp-derived products and products intended for sale outside Minnesota. It modifies who may hold which licenses, allows municipalities to hold cannabis and hemp licenses in certain circumstances, and updates local government authority over zoning, retail registrations, and event sales. The bill also changes cannabis event rules, transportation requirements, testing facility accreditation, and license application requirements, including labor peace agreement and social equity-related provisions.
A major part of the bill concerns criminal justice and civil protections. It expands expungement and resentencing eligibility for certain cannabis offenses, directs the Cannabis Expungement Board to review and act on qualifying cases, and requires the office to submit a future proposal on streamlining the cannabis supply chain. The bill also strengthens protections for patients, caregivers, and tribal program participants in areas such as employment, housing, school enrollment, custody, medical care, and access to health care facilities, while limiting law enforcement access to registry data and restricting use of registry information in criminal proceedings.
The overall sentiment reflected in the voting history appears mixed but ultimately supportive enough to advance the bill through both chambers, though by narrow margins in the Senate. The Senate passed an amended version 33-32 and later repassed the conference report 33-33, indicating significant division. The House passed the bill more comfortably, 82-50 and later 80-50 on the conference report. The lack of committee transcript detail limits insight into specific arguments, but the close Senate votes suggest the bill drew substantial support from cannabis policy reform advocates and meaningful opposition from members concerned about regulation, public safety, market structure, or the scope of legalization-related changes.
The main points of contention appear to be the breadth of the regulatory overhaul and the balance between access and control. Likely disputed issues include the expansion of hemp-derived cannabinoid sales and delivery, the treatment of artificially derived cannabinoids, the extent of municipal and tribal authority, labor and ownership requirements, and the expungement provisions for prior cannabis offenses. The bill also makes detailed changes to testing, labeling, and transport rules, which suggests debate over consumer safety, enforcement, and how tightly the market should be regulated.
The bill amends numerous sections of Minnesota Statutes governing cannabis, hemp, medical cannabis, expungement, data practices, and local licensing authority, and it adds new provisions in chapter 342. It shifts medical cannabis oversight to the Office of Cannabis Management, creates new hemp business license categories and endorsements, revises product limits and labeling requirements, and expands protections and eligibility rules for patients, caregivers, tribal programs, and people seeking expungement or resentencing for cannabis-related offenses. It also repeals several older provisions, including the Department of Health commissioner definition for the medical cannabis chapter and a transporter delivery-randomization requirement.
The bill appears to have received enough support to pass both chambers, but the vote margins show clear partisan and policy division, especially in the Senate. The House approved it by wider margins, while the Senate passed and later repassed the conference report by only one vote or a tie-breaking margin, indicating a contentious but ultimately successful effort to advance a broad cannabis policy package. The available record does not include committee transcript detail, so the sentiment can only be inferred from the close votes and the bill’s expansive scope.
The most notable areas of contention are the bill’s expansion of hemp-derived cannabinoid commerce, the creation of new wholesaler and exporter pathways, the rules for lower-potency hemp edibles and artificially derived cannabinoids, and the extent of local and tribal control over cannabis licensing and operations. Another likely flashpoint is the bill’s broad expungement and resentencing provisions for cannabis offenses, along with the labor peace, ownership, and social equity requirements imposed on license applicants. Supporters likely viewed these as necessary modernization and equity measures, while opponents likely saw them as too expansive, too permissive, or too complex to administer safely.